WEHI-P8

• Description :

  WEHI-P8 is an orally active inhibitor targeting the papain-like protease (PLpro) of coronaviruses. WEHI-P8 againsts SARS-CoV-2 PLpro with an IC50 value of 12 nM. WEHI-P8 has good cellular activity with a EC50 of 298 nM. WEHI-P8 protects mice from SARS-CoV-2 induced long-term symptoms in lung and brain. WEHI-P8 can be used for post-acute sequelae of COVID-19 study[1].

• UNSPSC :

  12352005

• Target :

  SARS-CoV

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Smiles :

  CCO/N=C([C@@H]1CCCN(C1)[C@H]2CC[C@H](CC2)O)/C3=CC4=C(C=C(C=C4)OC)C=C3

• Molecular Formula :

  C25H34N2O3

• Molecular Weight :

  410.55

• References & Citations :

  [1]M Bader S, et al. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nat Commun. 2025 Apr 3;16 (1) :2900.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported